• About us
    • About Lindahl
    • How we work
    • Said about Lindahl
    • Press
    • Find us
    • Privacy
  • Areas
    • Commercial dispute resolution
    • IT/Tech
    • Intellectual property
    • Life Sciences
    • M&A
    • All areas
  • Our people
    • Stockholm
    • Göteborg
    • Malmö
    • Uppsala
    • Helsingborg
    • Örebro
  • Latest news
    • Cases and transactions
    • News
    • Events
    • Knowledge
    • Portraits
  • Offices
    • Stockholm
    • Göteborg
    • Malmö
    • Uppsala
    • Örebro
    • Helsingborg

Lindahl has assisted Orexo with the acquisition of exclusive distribution rights in the USA

  • Home
  • Latest news
  • Cases and transactions
  • 2020
  • Lindahl has assisted Orexo with the acquisition of exclusive distribution rights in the USA

Lindahl served as advisor to Orexo AB (publ) when it acquired the exclusive rights from GAIA AG to distribute the digital therapy tool deprexis® in the United States.

deprexis® is a fully automated therapy developed by GAIA. It provides the user with personalised cognitive behavioural therapy interventions for managing symptoms of depression. The effectiveness of deprexis® has been evaluated and published in 13 randomised clinical trials that have included more than 2,500 patients. Orexo and GAIA expect that the COVID-19 crisis and the actions taken to control the pandemic will result in a significant rise in mental illness, such as depression, and consequently an increased need for digital therapies. Orexo is aiming to launch deprexis® on the US market during the summer of 2020. The annual net sales potential of deprexis® is expected to exceed USD 150 m – 225 million. At the time of writing, deprexis® has already been launched in multiple countries globally.

Orexo develops pharmaceuticals and digital therapies that meet an important need, particularly in the treatment of abuse and addiction. The products are commercialised independently in the USA or through partners worldwide. The main market for buprenorphine/naloxone products is currently the American market, where Orexo commercialises its lead product Zubsolv® for treatment of opioid use disorder. In 2019, the company’s total net sales reached SEK 845 million and it had 127 employees. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the USA. The company’s head office is in Uppsala, Sweden, where it conducts its research and development activities.

The law firm Lindahl has served as legal advisor to Orexo and the team has comprised Patrik Rindstål (responsible partner) and Mikael Olsson (GDPR).​

 

Life Sciences

Lindahl is one of the leading Scandinavian law firms within the field of life sciences. We have extensive experience in assisting both smaller and larger companies with competencies that span from commercial agreements and intellectual property rights through to transactions, regulatory matters and more.

Visit page

Strategic contracts

The rise in globalisation and competition makes it increasingly important for companies to enter into strategic partnerships and cooperative agreements.

Visit page

Contact

  • Patrik Rindstål

    Uppsala

    patrik.rindstal@lindahl.se +46 766 170 798
  • Mikael Olsson

    Uppsala

    mikael.olsson@lindahl.se +46 18 161 826
Pages
  • Start
  • About us
  • Areas
  • Our people
  • Latest news
  • Privacy
Our offices
  • Stockholm reception.stockholm@lindahl.se +46 8 527 70 800
  • Göteborg reception.goteborg@lindahl.se +46 31 799 10 00
  • Malmö reception.malmo@lindahl.se +46 40 664 66 50
  • Uppsala reception.uppsala@lindahl.se +46 18 16 18 50
  • Örebro reception.orebro@lindahl.se +46 19 20 89 00
  • Helsingborg reception.helsingborg@lindahl.se +46 42 17 53 00
Social media
  • Connect with us on social networks: Instagram, Linkedin, Youtube, Facebook,

Disclaimer

The material and information on this site is intended for general informational purposes only and does not constitute legal advice on any specific matter. Please note that all images on Lindahl's website, www.lindahl.se, are subject to intellectual property protection and downloading, publication, copying and/or other use of the images requires the written consent of the rights holder. You'll find Advokatfirman Lindahl KB's general terms and conditions here.

Some cookies are essential, others help us improve your experience by providing insights into how the site is used. For more information, please visit our Cookie Policy.

Essential Cookies

These cookies are necessary for the functionality of the site and cannot be disabled.

Analytics Cookies>

We use Analytics cookies to collect information that gives us insight into how our website is being used. We anonymize IP addresses in Google Analytics. By clicking on Decline we won't save theese cookies.

Decline
We use cookies to get insights on how our site is used and give our visitors the best possible experience